HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BMY 27709

structure given in first source

Also Known As:

BMY-27709

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolizines: 1
      - BMY 27709: 4

Experts

1.	Cianci, C: 2 articles (09/2001 - 08/2000)
2.	Danetz, S: 2 articles (09/2001 - 08/2000)
3.	Krystal, M: 2 articles (09/2001 - 08/2000)
4.	Luo, G: 2 articles (09/2001 - 08/2000)
5.	Meanwell, N A: 2 articles (09/2001 - 08/2000)
6.	Tiley, L: 2 articles (09/2001 - 08/2000)
7.	Torri, A: 2 articles (09/2001 - 08/2000)
8.	Wei, J: 2 articles (09/2001 - 08/2000)
9.	Yu, K L: 2 articles (09/2001 - 08/2000)
10.	Hsieh, Hsing-Pang: 1 article (01/2007)

Related Diseases

1.	Human Influenza (Influenza) 12/01/1996 - "However, BMY-27709 was found to be inactive against H3 subtype viruses, as well as influenza B/Lee/40 virus. " 09/03/2001 - "Structure-activity studies associated with the salicylic acid-derived inhibitor of influenza fusion, BMY-27709, were examined using a parallel synthesis approach. " 08/07/2000 - "Structural variation of the quinolizidine heterocycle of the influenza fusion inhibitor BMY-27709 was examined by several topological dissections in order to illuminate the critical features of the ring system. "
2.	Infections 12/01/1996 - "BMY-27709 was also found to act against H1 and H2 viruses early in infection, suggesting that the target for inhibition is the hemagglutinin protein. " 01/01/2007 - "For instance, included are descriptions of (1) inhibitors of HA cleavage, such as nafamostat, camostat, gabexate, epsilon-aminocapronic acid and aprotinin, (2) inhibitors of fusion and entry, such as benzoquinones and hydroquinones, CL 385319, BMY-27709, stachyflin, and their analogues, (3) inhibitors of viral RNPs/polymerase/endonuclease, such as T-705, L-735,822, flutimide and their analogues, (4) inhibitors of MEK, such as PD 0325901, CI-1040 and ARRY-142886, and (5) inhibitors of NA such as DANA, FANA, zanamivir, and oseltamivir, etc. Although amantadine and rimantadine are not recommended for treating influenza virus infections because of drug resistance problem, these viral M2 ion channel blockers established a proof-of-concept that the endocytosis of virion into host cells can be a valid drug target because M2 protein is involved in the endocytosis process. "
3.	Hemolysis 12/01/1996 - "BMY-27709 is able to inhibit virus-induced red blood cell hemolysis, suggesting that it blocks the membrane fusion function of hemagglutinin. "

Related Drugs and Biologics

1.	Salicylic Acid (2 Hydroxybenzoic Acid)
2.	Proteins (Proteins, Gene)
3.	Quinolizidines
4.	Zanamivir (Relenza)
5.	Oseltamivir (Tamiflu)
6.	Mitogen-Activated Protein Kinase Kinases (MEKs)
7.	Gabexate (Foy)
8.	Benzoquinones
9.	Rimantadine
10.	Aprotinin (Trasylol)